Skip to contents

Seo Young Kim, MD, ScD, MSCE
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Phar Epid & Phar Econ
75 Francis Street
Boston, MA 02115

Research Location: One Brigham Circle

Fax: 617-232-8602
Email: skim62@partners.org

Edit Profile


Research Narrative:

Seoyoung C. Kim, MD, ScD, MSCE, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics and coappointed in the Division of Rheumatology, Immunology and Allergy at the Brigham and Women’s Hospital. Her research focuses on comparative safety and effectiveness of medications for the rheumatic diseases as well as health services/outcome research in Rheumatology.

Dr. Kim has received several NIH research grants including a current R01 study to determine the safey of long-term opioid use in patients undergoing total joint replacement for hip or knee arthritis.  

 


Education:
Harvard School of Public Health, 2014, ScD
University of Pennsylvania , 2009, MSCE
Hanyang University, College of Medicine, 2000, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. JAMA Dermatol. 2019 Mar 27.

2. Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care Res (Hoboken). 2019 Mar; 71(3):427-434.

3. Yoshida K, Solomon DH, Haneuse S, Kim SC, Patorno E, Tedeschi SK, Lyu H, Franklin JM, Stürmer T, Hernández-Díaz S, Glynn RJ. Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. Am J Epidemiol. 2019 Mar 01; 188(3):609-616.

4. Tedeschi SK, Kim SC, Guan H, Grossman JM, Costenbader KH. Comparative Fracture Risks among US Medicaid Enrollees with and without Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Feb 04.

5. Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J, Solomon DH, Katz JN, Kim SC. Association of geography and access to healthcare providers with long term prescription opioid use in Medicare patients with severe osteoarthritis: A cohort study. Arthritis Rheumatol. 2019 Jan 28.

6. Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 Apr; 78(4):456-464.

7. Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann Intern Med. 2019 Jan 01.

8. Chen SK, Liao KP, Liu J, Kim SC. Risk of Hospitalized Infection and Initiation of Abatacept versus TNF Inhibitors among Patients with Rheumatoid Arthritis: a Propensity Score-Matched Cohort Study. Arthritis Care Res (Hoboken). 2018 Dec 20.

9. Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients. Arthritis Rheumatol. 2018 Dec 15.

10. Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Circulation. 2018 Sep 11; 138(11):1116-1126.